US Congress Increases Funding for Prostate Cancer Research for FY 2020

US Congress Increases Funding for Prostate Cancer Research for FY 2020
To foster more research projects in prostate cancer, the U.S. Congress has increased funding for the Department of Defense’s Prostate Cancer Research Program (PCRP) by $10 million, to $110 million, for fiscal year 2020. The congressional action marks the third $10 million PCRP hike in four years, according to ZERO — The End of Prostate Cancer, a nonprofit that advances research and works to improve the lives of patients and their families. “Patients like Steve Bleser with advanced prostate cancer have limited treatment options,” Jamie Bearse, ZERO CEO, said in a press release. “With this additional research funding from Congress, Steve and patients across the nation can now have hope that new breakthroughs will be in the pipeline. Amazing milestones like this only happen because of our dedicated and passionate champions from around the country who are tireless in sharing our mission to end prostate cancer.” A North Carolina resident and prostate cancer advocate, Bleser recently shared his story with legislators. He’s also attended the ZERO Prostate Cancer Summit, an annual event on Capitol Hill in Washington, D.C., that brings awareness to the need for more prostate cancer research funding. “I’ve done chemo, radiation, and many other treatments. My doctors say there are no more options for me,” Bleser said. “This is unacceptable. I won’t give up this fight — funding research is critical
Subscribe or to access all post and page content.